IMVT News and Press, Immunovant Inc.

2024-07-12 10:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-07-10 12:19:05 ET Summary argenx SE's stock is down significantly from its all-time highs due to some clinical failures for its primary asset, Vyvgart. However, recent approval for a label expansion into CIDP has turned sentiment more positive, with the shares spurting forwar...

2024-06-28 10:20:00 ET Summary Argenx's shares rose after FDA approval of Vyvgart for the treatment of CIDP. The approval expands the addressable market for Vyvgart, and the company will initially target 12,000 patients in the U.S. who are currently not well controlled on other dr...

2024-06-28 04:39:01 ET Summary Immunovant, Inc. is a clinical-stage biopharmaceutical company developing autoimmune disease therapies targeting the neonatal Fc receptor [FcRn]. IMVT's leading drug candidate, Batoclimab, shows promise in clinical trials for conditions like myasthen...

2024-06-27 10:16:11 ET Summary Immunovant listed on Nasdaq in 2019 through a SPAC with Roivant Sciences as majority owner, focusing on developing drugs for autoimmune diseases, notable the FcRn inhibitor batoclimab. Batoclimab, faced safety issues leading to stock declines, after ...

2024-06-12 13:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-02 07:27:01 ET Summary Roivant Sciences' stock is undervalued with a market cap of $8.37 billion and $6 billion in cash. The company holds stakes in biotech companies worth billions, including Immunovant and Arbutus. Genevant and Arbutus offer potential litigation valu...

2024-05-29 17:05:50 ET More on Immunovant Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade) Seeking Alpha’s Quant Rating on Immunovant Historical earnings data for Immunovant Financial information for Immunovant Read the fu...

2024-05-29 16:54:07 ET Gainers: OneMedNet  ( ONMD ) +63% . Red Robin Gourmet Burgers ( RRGB ) +10% . Petco Health and Wellness Company ( WOOF ) +5% . Radius Recycling ( RDUS ) +5% . Office Properties Income  ( OPI ) +5% ...

Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and other therapeutic areas over this fiscal year ending March 31, 2025 Topline data from the bato...